Patents by Inventor Zhijun Wu
Zhijun Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10038437Abstract: Disclosed is a high voltage power system with enable control, comprising a high voltage start-up circuit, a PWM control module, and a driving module; the high voltage start-up circuit comprises a first transistor, a third transistor, a fourth transistor, a resistor, a diode, a VDD detection unit and an I/O interface unit; the high voltage start-up circuit is controlled by an input of a pin EN; when the pin EN is set, the high voltage start-up circuit stops working; the power system is shut off and doesn't restart, and enters a zero standby state; when the pin EN is reset, the high voltage start-up circuit restores to work, and the power system restarts and enters a normal working state. The power system having the high voltage start-up circuit with enable control has characteristics that the standby input power consumption and standby input current are both close to zero.Type: GrantFiled: November 9, 2016Date of Patent: July 31, 2018Assignee: WUXI CHIPOWN MICRO-ELECTRONICS LIMITED NEW DISTRICTInventors: Haisong Li, Changshen Zhao, Yangbo Yi, Wenliang Liu, Zhijun Wu
-
Publication number: 20170338811Abstract: Disclosed is a high voltage power system with enable control, comprising a high voltage start-up circuit, a PWM control module, and a driving module; the high voltage start-up circuit comprises a first transistor, a third transistor, a fourth transistor, a resistor, a diode, a VDD detection unit and an I/O interface unit; the high voltage start-up circuit is controlled by an input of a pin EN; when the pin EN is set, the high voltage start-up circuit stops working; the power system is shut off and doesn't restart, and enters a zero standby state; when the pin EN is reset, the high voltage start-up circuit restores to work, and the power system restarts and enters a normal working state. The power system having the high voltage start-up circuit with enable control has characteristics that the standby input power consumption and standby input current are both close to zero.Type: ApplicationFiled: November 9, 2016Publication date: November 23, 2017Inventors: HAISONG LI, CHANGSHEN ZHAO, YANGBO YI, WENLIANG LIU, ZHIJUN WU
-
Patent number: 7968548Abstract: Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: GrantFiled: August 11, 2006Date of Patent: June 28, 2011Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Kevin D. Burris, Zhijun Wu, Papireddy Purma, Yadi Reddy Bonuga
-
Patent number: 7964601Abstract: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: GrantFiled: June 2, 2008Date of Patent: June 21, 2011Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Ramesh Rajpurohit, Zhijun Wu, Papireddy Purma, Annette M. Shadiack, Kevin D. Burris
-
Patent number: 7807678Abstract: The invention relates to a method of deriving a peptidomimetic of a biologically active metallopeptide, wherein the peptidomimetic includes at least one non-peptide ring structure defining a template space superimposable on a corresponding defined template space of the metallopeptide, and where the peptidomimetic further includes at least two elements independently including an amino acid residue, amino acid side chain moiety or derivative thereof, the elements defining and occupying a similar descriptor space as corresponding elements of the metallopeptide. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5- and 6-5-bicyclic fused ring structure melanocortin receptor-specific peptidomimetics.Type: GrantFiled: February 10, 2004Date of Patent: October 5, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Patent number: 7732451Abstract: A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula: where R1 is a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, and L, R2, R3 and Rx are as defined in the specification.Type: GrantFiled: January 14, 2005Date of Patent: June 8, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Annette M. Shadiack, Yiqun Shi, Zhijun Wu, Ramesh Rajpurohit, Kevin D. Burris, Papireddy Purma
-
Patent number: 7727991Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: GrantFiled: August 11, 2006Date of Patent: June 1, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Kevin D. Burris, Zhijun Wu, Papireddy Purma, Yadi Reddy Bonuga
-
Patent number: 7727990Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: GrantFiled: August 11, 2006Date of Patent: June 1, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Kevin D. Burris, Zhijun Wu, Papireddy Purma, Yadi Reddy Bonuga
-
Patent number: 7718802Abstract: Melanocortin receptor-specific compounds of the general formulas and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, L is a linker, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q includes a substituted or unsubstituted aromatic carbocyclic ring, R6, R7, y and z are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration, and optionally with one or two additional ring substituents as defined, which compounds bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: GrantFiled: April 5, 2005Date of Patent: May 18, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Ramesh Rajpurohit, Zhijun Wu
-
Patent number: 7709484Abstract: A substituted piperazine compound having the structure I: or the structure IX: or an enantomeric, stereoisomeric or diastereomeric form of the foregoing, and pharmaceutically acceptable salts thereof, where J, L, Q, W, A, R6, R7, z and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration, which compounds bind to one or more melanocortin receptors and may be employed in pharmaceutical preparations for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: GrantFiled: April 19, 2005Date of Patent: May 4, 2010Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Bolun Hu, Ramesh Rajpurohit
-
Patent number: 7601753Abstract: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: GrantFiled: March 1, 2007Date of Patent: October 13, 2009Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Patent number: 7456184Abstract: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: GrantFiled: April 30, 2004Date of Patent: November 25, 2008Assignee: Palatin Technologies Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit, Annette M. Shadiack, Papireddy Purma, Kevin D. Burris
-
Publication number: 20080234289Abstract: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.Type: ApplicationFiled: June 2, 2008Publication date: September 25, 2008Applicant: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Ramesh Rajpurohit, Zhijun Wu, Papireddy Purma, Annette M. Shadiack, Kevin D. Burris
-
Patent number: 7354923Abstract: Melanocortin receptor-specific piperazine or ketopiperazine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where X is CH2 or C?O, R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group, a second amino acid residue or a second amino acid residue with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: GrantFiled: January 21, 2004Date of Patent: April 8, 2008Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Patent number: 7326707Abstract: Melanocortin receptor-specific bicyclic compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, R3 X and z are as described in the specification, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: GrantFiled: January 21, 2004Date of Patent: February 5, 2008Assignee: Palatin Technologies IncorporatedInventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Publication number: 20070155670Abstract: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: ApplicationFiled: March 1, 2007Publication date: July 5, 2007Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Patent number: 7189755Abstract: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: GrantFiled: February 10, 2004Date of Patent: March 13, 2007Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Publication number: 20060287331Abstract: Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA
-
Publication number: 20060287332Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA
-
Publication number: 20060287330Abstract: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.Type: ApplicationFiled: August 11, 2006Publication date: December 21, 2006Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh SHARMA, Yi-Qun SHI, Kevin BURRIS, Zhijun WU, Papireddy PURMA, Yadi Reddy BONUGA